Brought to you by 
MedImmune Ventures leads Hydra's Series D round
16 Jan 2009
Executive Summary
Hydra Biosciences (developing ion channel therapeutics) raised $22mm through its Series D round, which was led by MedImmune Ventures and included returning investors Advanced Technology Ventures, Abingworth, Polaris Venture Partners, BioVentures Investors, Biogen Idec New Ventures, and Lilly Ventures. An executive from AstraZeneca, as designee for MedImmune and MedImmune Ventures, will take a seat on Hydra's board. The company will use the proceeds to advance its Transient Receptor Potential ion channel drug programs into clinical trials for pain, inflammation, and pulmonary diseases.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MedImmune Ventures leads Hydra's Series D round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice